2026.8.21

TBMC and Caarlogic Biomed Initiate Lentiviral Vector Collaboration, Bridging Taiwan’s Advanced Therapy R&D and Manufacturing

Taiwan Bio-Manufacturing Corporation (TBMC), a premier contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Caarlogic Biomed Co., Ltd. (Caarlogic Biomed). Under the agreement, TBMC will provide comprehensive process development, GMP manufacturing, quality control, and analytical testing services for GMP-grade lentiviral vectors supporting Caarlogic Biomed’s advanced CAR-T pipeline. This partnership establishes a robust manufacturing and quality infrastructure to accelerate subsequent Investigational New Drug (IND) applications.

Focusing on the A-DASH BCMA × ISER Dual CAR-T Candidate

Caarlogic Biomed is currently developing its A-DASH (Asymmetric Dual Signaling Hierarchical) BCMA × ISER dual CAR-T platform, with multiple myeloma as its lead indication. The asymmetric, hierarchical dual-signaling architecture enables the anti-BCMA CAR to mediate tumor recognition, while the ISER enhances T-cell persistence and functionality within the immunosuppressive tumor microenvironment. Through this division of functions across different modules, the platform aims to enhance tumor recognition, reduce the risk of antigen escape, and improve CAR-T cell functionality and persistence within the tumor microenvironment.
Due to the extended genetic sequences required for dual-receptor constructs, maintaining viral vector yield, stability, and manufacturing consistency becomes a key challenge for clinical-scale production.

TBMC Brings CRDMO Expertise in Viral Vectors and Advanced Therapies

Due to the extended genetic sequences required for dual-receptor constructs, maintaining viral vector yield, stability, and manufacturing consistency becomes a key challenge for clinical-scale production.
TBMC’s Zhubei GMP facility, inaugurated in March 2026, includes dedicated production suites and quality control laboratories for viral vectors, mRNA therapeutics and cell therapy. The company offers integrated CDMO services spanning process development, GMP manufacturing, fill-finish operations, and analytical testing, providing the capabilities required to advance therapies from research and development through clinical-stage production.
Through this partnership, TBMC will provide end-to-end support—encompassing vector engineering, process scale-up, analytical development, GMP clinical batch manufacturing, and regulatory filing support—ensuring a seamless transition from preclinical proof-of-concept to human clinical trials.
In this collaboration, the two companies will focus on lentiviral vectors required for Caarlogic Biomed’s CAR-T candidate, integrating key capabilities across product design, vector engineering, process scale-up, quality analysis, manufacturing management, and regulatory submission preparation to strengthen the critical translational bridge between preclinical research and IND applications.
Together, the two companies will connect Taiwan’s domestic innovation and R&D with process development, quality management, and GMP manufacturing capabilities, strengthening the quality and manufacturing readiness of the candidate and enabling Taiwan-developed innovative therapies to take a meaningful step forward toward clinical translation.